Literature DB >> 21228351

HCV peptide (C5A), an amphipathic α-helical peptide of hepatitis virus C, is an activator of N-formyl peptide receptor in human phagocytes.

Qing Lin1, Dan Fang, Xinwei Hou, Yingying Le, Jiazhu Fang, Feng Wen, Wanghua Gong, Keqiang Chen, Ji Ming Wang, Shao Bo Su.   

Abstract

The hepatitis C virus (HCV) nonstructural 5A, a phosphorylated zinc metalloprotein, is an essential component of the HCV replication complex. An amphipathic α-helical peptide (HCV peptide [C5A]) derived from nonstructural 5A membrane anchor domain possesses potent anti-HCV and anti-HIV activity in vitro. In this study, we aimed to investigate the potential of HCV peptide (C5A) to regulate host immune responses. The capacity of HCV peptide (C5A) in vitro to induce migration and calcium mobilization of human phagocytes and chemoattractant receptor-transfected cells was investigated. The recruitment of phagocytes in vivo induced by HCV peptide (C5A) and its adjuvant activity were examined. The results revealed that HCV peptide (C5A) was a chemoattractant and activator of human phagocytic leukocytes by using a G-protein coupled receptor, namely formyl peptide receptor. In mice, HCV peptide (C5A) induced massive phagocyte infiltration after injection in the air pouch or the s.c. region. HCV peptide (C5A) also acted as an immune adjuvant by enhancing specific T cell responses to Ag challenge in mice. Our results suggest that HCV peptide (C5A) derived from HCV regulates innate and adaptive immunity in the host by activating the formyl peptide receptor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228351      PMCID: PMC7385933          DOI: 10.4049/jimmunol.1002340

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Pleiotropic roles of formyl peptide receptors.

Authors:  Y Le; J J Oppenheim; J M Wang
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

2.  Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease.

Authors:  Arantxa Apolinario; Pedro L Majano; Eduardo Alvarez-Pérez; Alicia Saez; Carlos Lozano; Javier Vargas; Carmelo García-Monzón
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

3.  Formylpeptide receptor FPR and the rapid growth of malignant human gliomas.

Authors:  Ye Zhou; Xiuwu Bian; Yingying Le; Wanghua Gong; Jinyue Hu; Xia Zhang; Lihua Wang; Pablo Iribarren; Rosalba Salcedo; O M Zack Howard; William Farrar; Ji Ming Wang
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

Review 4.  Lymphocyte traffic control by chemokines.

Authors:  B Moser; P Loetscher
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

5.  A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Authors:  Guofeng Cheng; Ana Montero; Pablo Gastaminza; Christina Whitten-Bauer; Stefan F Wieland; Masanori Isogawa; Brenda Fredericksen; Suganya Selvarajah; Philippe A Gallay; M Reza Ghadiri; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Functional activation of the formyl peptide receptor by a new endogenous ligand in human lung A549 cells.

Authors:  Ursula Rescher; Antje Danielczyk; Arseni Markoff; Volker Gerke
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

7.  Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T lymphocytes from patients with chronic hepatitis C infection.

Authors:  Mathias Lichterfeld; Ludger Leifeld; Hans Dieter Nischalke; Jürgen K Rockstroh; Lothar Hess; Tilman Sauerbruch; Ulrich Spengler
Journal:  J Infect Dis       Date:  2002-05-20       Impact factor: 5.226

8.  Cleavage of the hepatitis C virus NS5A protein by caspase-3 in the interferon sensitivity-determining region in a sequence-dependent manner.

Authors:  Rachmat Hidajat; Motoko Nagano-Fujii; Lin Deng; Hak Hotta
Journal:  Kobe J Med Sci       Date:  2004

9.  N-formylpeptide and complement C5a receptors are expressed in liver cells and mediate hepatic acute phase gene regulation.

Authors:  R McCoy; D L Haviland; E P Molmenti; T Ziambaras; R A Wetsel; D H Perlmutter
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

10.  Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Authors:  Katharina B Rothwangl; Balaji Manicassamy; Susan L Uprichard; Lijun Rong
Journal:  Virol J       Date:  2008-03-20       Impact factor: 4.099

View more
  14 in total

1.  Formylpeptide receptor 1 mediates the tumorigenicity of human hepatocellular carcinoma cells.

Authors:  Liang Zhang; Huanyu Wang; Tianshu Yang; Zhifeng Su; Dan Fang; Yafeng Wang; Jiazhu Fang; Xinwei Hou; Yingying Le; Keqiang Chen; Ji Ming Wang; Shao Bo Su; Qing Lin; Qi Zhou
Journal:  Oncoimmunology       Date:  2015-08-24       Impact factor: 8.110

Review 2.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

3.  Antiviral peptide nanocomplexes as a potential therapeutic modality for HIV/HCV co-infection.

Authors:  Jinjin Zhang; Andrea Mulvenon; Edward Makarov; Jill Wagoner; Jaclyn Knibbe; Jong Oh Kim; Natalia Osna; Tatiana K Bronich; Larisa Y Poluektova
Journal:  Biomaterials       Date:  2013-02-10       Impact factor: 12.479

4.  HSV neutralization by the microbicidal candidate C5A.

Authors:  Lot de Witte; Michael D Bobardt; Udayan Chatterji; Freek B van Loenen; Georges M G M Verjans; Teunis B H Geijtenbeek; Philippe A Gallay
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

5.  A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2.

Authors:  Peiqi Yin; Ling Zhang; Fei Ye; Yao Deng; Sha Lu; Yi-Ping Li; Leiliang Zhang; Wenjie Tan
Journal:  Sci Rep       Date:  2017-06-21       Impact factor: 4.379

Review 6.  Why whey? Camel whey protein as a new dietary approach to the management of free radicals and for the treatment of different health disorders.

Authors:  Gamal Badr; Nancy K Ramadan; Leila H Sayed; Badr M Badr; Hossam M Omar; Zeliha Selamoglu
Journal:  Iran J Basic Med Sci       Date:  2017-04       Impact factor: 2.699

7.  Key genes associated with non-alcoholic fatty liver disease and acute myocardial infarction.

Authors:  Weiran Dai; Yue Sun; Zhiyuan Jiang; Kuan Du; Ning Xia; Guoqiang Zhong
Journal:  Med Sci Monit       Date:  2020-06-28

8.  V101L of human formyl peptide receptor 1 (FPR1) increases receptor affinity and augments the antagonism mediated by cyclosporins.

Authors:  Caihong Zhou; Yan Zhou; Jia Wang; Yang Feng; Haonan Wang; Jinglun Xue; Yani Chen; Richard D Ye; Ming-Wei Wang
Journal:  Biochem J       Date:  2013-04-15       Impact factor: 3.857

9.  Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.

Authors:  Elrashdy M Redwan; Esmail M El-Fakharany; Vladimir N Uversky; Mustafa H Linjawi
Journal:  BMC Complement Altern Med       Date:  2014-07-03       Impact factor: 3.659

10.  The Synthesis of Molecular Docking Studies, In Vitro Antimicrobial and Antifungal Activities of Novel Dipeptide Derivatives Based on N-(2-(2-Hydrazinyl-2-oxoethylamino)-2-oxoethyl)-nicotinamide.

Authors:  Gaber Moustafa; Hemat Khalaf; Ahmed Naglah; Asma Al-Wasidi; Nawal Al-Jafshar; Hassan Awad
Journal:  Molecules       Date:  2018-03-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.